![Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
24 March 2021
Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021
ENTEROME SA, a clinical stage biopharmaceutical...